Sulcardine administration for treatment of acute atrial fibrillation
AssigneeHUYABIO International, LLC
InventorsSuzanne J. Romano, Gary T. Elliott
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
Claims24
A pharmaceutical composition comprising a compound, which is N-[4-hydroxy-3,5-bis(1-pyrrolidinylmethyl)benzyl]-4-methoxybenzenesulfonamide or a pharmaceutically acceptable salt thereof, wherein the composition produces pan-ECG parameter changes including:
- increase in QRS, PDur, PR, and QTcF or reduction of JTp;
- and no effect on TpTe or increase in TpTe.
A method of treating atrial fibrillation (AF), comprising intravenously administering to a human subject in need thereof sulcardine, or a pharmaceutically acceptable salt thereof, resulting in increase in QRS, PDur, PR, and QTcF, and reduction of JTp, and no effect or increase in TpTe.
The method of treating atrial fibrillation (AF), comprising intravenously administering to a human subject in need thereof a therapeutically effective amount of sulcardine, or a pharmaceutically acceptable salt thereof, such that the plasma concentration of sulcardine in said human subject at the end of the administration is from about 370 ng/ml to about 8,000 ng/ml, and said plasma concentration of sulcardine decreases by at least about 75% within about 1 hour.
Dependencies are inferred from the claim text.